Literature DB >> 15572723

Postmarketing surveillance--lack of vigilance, lack of trust.

Phil B Fontanarosa, Drummond Rennie, Catherine D DeAngelis.   

Abstract

Keywords:  Health Care and Public Health

Mesh：

Year:  2004        PMID： 15572723     DOI： 10.1001/jama.292.21.2647

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  33 in total

1.  A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.

Authors:  Ben Y Reis; Karen L Olson; Lu Tian; Rhonda L Bohn; John S Brownstein; Peter J Park; Mark J Cziraky; Marcus D Wilson; Kenneth D Mandl
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

2.  Stakeholder Satisfaction with the Australian Rheumatology Association Database (ARAD).

Authors:  Andrew M Briggs; Lyn March; Rosemarie van den Haak; Nino Hay; Lyndall Henderson; Bridget Murphy; Lainie Wengier; Marissa Lassere; Andrea Bendrups; Rachelle Buchbinder
Journal:  Patient       Date:  2009-03-01       Impact factor: 3.883

3.  Is there still a role for spontaneous reporting of adverse drug reactions?

Authors:  Joel Lexchin
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

4.  Discussion point: should governments buy drug patents?

Authors:  Juan del Llano
Journal:  Eur J Health Econ       Date:  2007-06

Review 5.  How can we regulate medicines better?

Authors:  Silvio Garattini; Vittorio Bertele'
Journal:  BMJ       Date:  2007-10-20

6.  Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal.

Authors:  Maria T Herdeiro; Jorge Polónia; Juan J Gestal-Otero; Adolfo Figueiras
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

7.  Electronic nicotine delivery systems: a research agenda.

Authors:  Jean-François Etter; Chris Bullen; Andreas D Flouris; Murray Laugesen; Thomas Eissenberg
Journal:  Tob Control       Date:  2011-03-17       Impact factor: 7.552

Review 8.  Today's challenges in pharmacovigilance: what can we learn from epoetins?

Authors:  Hans C Ebbers; Aukje K Mantel-Teeuwisse; Ellen H M Moors; Huub Schellekens; Hubert G Leufkens
Journal:  Drug Saf       Date:  2011-04-01       Impact factor: 5.606

9.  Postmarketing Research and Surveillance: Issues and Challenges.

Authors:  David B Resnik
Journal:  Monitor (Assoc Clin Pharmacol)       Date:  2008-04

10.  Beyond post-marketing research and MedWatch: Long-term studies of drug risks.

Authors:  David B Resnik
Journal:  Drug Des Devel Ther       Date:  2007-10-01       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.